ID
19935
Description
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. Documentation process: This form is to be obtained in week 24 and week 48.
Mots-clés
Versions (3)
- 30/01/2017 30/01/2017 -
- 31/01/2017 31/01/2017 -
- 31/01/2017 31/01/2017 -
Téléchargé le
31 janvier 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Antibody and Pharmacokinetics Pre- and Post-Dose CRFs Multiple Sclerosis Tysabri NCT00027300
Antibody and Pharmacokinetics Pre- and Post-Dose CRFs Multiple Sclerosis Tysabri NCT00027300
Similar models
Antibody and Pharmacokinetics Pre- and Post-Dose CRFs Multiple Sclerosis Tysabri NCT00027300
C1516698 (UMLS CUI [1,2])
C0031327 (UMLS CUI [1,2])
C0439565 (UMLS CUI [1,3])
C0439568 (UMLS CUI-2)
C0031327 (UMLS CUI [1,2])
C0439568 (UMLS CUI [1,3])